ArticlePharmaceutics2022
Design of Bio-Responsive Hyaluronic Acid-Doxorubicin Conjugates for the Local Treatment of Glioblastoma.
Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- Localized delivery of hyaluronic acid-doxorubicin from a surgical paste for post-operative glioblastoma treatment.Materials today. Bio · 2026Article
- Recent Advances in Nanoscale Sprayable Hydrogels for Cancer Management: Nanoparticle-Loaded Formulations for Therapy and Prevention.International journal of nanomedicine · 2026Review
- The Influence of Synthesis Parameters on the Properties of Dextran-Based Hydrogels for Colon-Targeted Antitumor Drug Delivery Part I: Room Temperature Synthesis of Dextran/Inulin Hydrogels for Colon-Targeted Antitumor Drug Delivery.Gels (Basel, Switzerland) · 2025Article
- Localized treatment of glioblastoma: a review of clinical strategies and advances in drug delivery systems.Nanomedicine (London, England) · 2025Review
- Phosphatidylcholine-derived carriers facilitate brain tumor delivery and enhance glioblastoma therapy.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Enhancing chemoimmunotherapy for colorectal cancer with paclitaxel and alantolactone via CD44-Targeted nanoparticles: A STAT3 signaling pathway modulation approach.Asian journal of pharmaceutical sciences · 2025Article
- Advancing Therapeutic Strategies with Polymeric Drug Conjugates for Nucleic Acid Delivery and Treatment.International journal of nanomedicine · 2025Review
- Article
- The Application of Ultrasmall Gold Nanoparticles (2 nm) Functionalized with Doxorubicin in Three-Dimensional Normal and Glioblastoma Organoid Models of the Blood-Brain Barrier.Molecules (Basel, Switzerland) · 2024Article
- Article
- Synergistic effect of doxorubicin lauroyl hydrazone derivative delivered by α-tocopherol succinate micelles for the treatment of glioblastoma.International journal of pharmaceutics: X · 2023Article
- Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation.Molecular cancer · 2023Review
- Hyaluronic acid-antigens conjugates trigger potent immune response in both prophylactic and therapeutic immunization in a melanoma model.Drug delivery and translational research · 2023Article
- En route to local glioblastoma treatment with temozolomide doped hyaluronan fibres: formulation andRSC medicinal chemistry · 2023Article
- Review
- A peroxidase-like magneto-gold nanozyme AuNC@FeFrontiers in bioengineering and biotechnology · 2023Article
- Hyaluronic Acid Scaffolds for Loco-Regional Therapy in Nervous System Related Disorders.International journal of molecular sciences · 2022Review
- Prostate Apoptosis Response-4 (Par-4): A Novel Target in Pyronaridine-Induced Apoptosis in Glioblastoma (GBM) Cells.Cancers · 2022Article
- Hyaluronic Acid: Known for Almost a Century, but Still in Vogue.Pharmaceutics · 2022Review
- Fabrication and Modelling of a Reservoir-Based Drug Delivery System for Customizable Release.Pharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Glioblastoma is an unmet clinical need. Local treatment strategies offer advantages, such as the possibility to bypass the blood-brain barrier, achieving high drug concentrations at the glioblastoma site, and consequently reducing systemic toxicity. In this study, we evaluated the feasibility of using hyaluronic acid (HA) for the local treatment of glioblastoma. HA was conjugated to doxorubicin (DOX) with distinct bio-responsive linkers (direct amide conjugation HA-NH-DOX), direct hydrazone conjugation (HA-Hz-DOX), and adipic hydrazone (HA-AdpHz-DOX). All HA-DOX conjugates displayed a small size (less than 30 nm), suitable for brain diffusion. HA-Hz-DOX showed the best performance in killing GBM cells in both 2D and 3D in vitro models and displayed superior activity in a subcutaneous GL261 tumor model in vivo compared to free DOX and other HA-DOX conjugates. Altogether, these results demonstrate the feasibility of HA as a polymeric platform for the local treatment of glioblastoma and the importance of rationally designing conjugates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.